KLRG1标记着与瘤进展和免疫治疗反应相关的瘤透的CD4 T细胞子集

Casey R Ager1,2,3,4, Mingxuan Zhang5,6, Matthew Chaimowitz3,7

  • 1Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, New York, USA ager.casey@mayo.edu bi2175@cumc.columbia.edu.

PubMed
概括

新的流细胞测量方法揭示了KLRG1+ CD4 T细胞作为癌症免疫力中的动态生物标志物. 这些特定的T细胞群体跟踪瘤负担和对免疫检查点阻塞 (ICB) 治疗的反应.